A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

This is a prospective Phase II study evaluating Siltuximab for CRS and ICANS after CAR-T infusion in multiple myeloma patients.

Trial Details

NCT ID
NCT07106671
Phase
PHASE2
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Siltuximab
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Be informed and voluntarily sign the Informed Consent Form (ICF).
  • Age ≥18 years old.
  • Diagnosed with multiple myeloma according to IMWG diagnostic criteria.
  • Developed CRS (grade ≥1) and/or ICANS (grade ≥1) after CAR-T treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →